Spinal Muscular Atrophy Market, By Disease Type (Type I, Type II, Type III, and Type IV), By Age (Infant and Adult), By Treatment (Drug Therapy and Gene Therapy) and By Region - Trends, Analysis and Forecast till 2034

Report Code: PMI8218 | Publish Date: March 2024 | No. of Pages: 180

Global Spinal Muscular Atrophy Market Companies

  • includes Biogen
  • Cytokinetics, Inc.
  • F. Hoffmann-La Roche
  • Novartis AG
  • Pfizer Inc.
  • Ionis Pharmaceuticals, Inc.

Recent News:

  • A new test to detect Spinal Muscular Atrophy (SMA) in infants is being introduced throughout Wessex in November 2023. As part of an Oxford University study, 8,000 newborns will be evaluated over the course of the following 14 months for this screening. Newborns with SMA have the best chance of living long, healthy lives if the condition is addressed when it is discovered at birth. Scientists can check for genetic markers in the baby's blood by pricking the heel as part of the screening process.
  • Biogen Inc. released fresh SPINRAZA (nusinersen) data in June 2023 with the goal of providing important information to the spinal muscular atrophy (SMA) community. This week in Orlando, Florida, Cure SMA is hosting the SMA Research & Clinical Care Meeting, where the statistics were presented.